Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 464-472

  Breitenstein, Alexander ^a,b   Stein, Sokrates ^a   Holy, Erik W ^a,b   Camici, Giovanni G ^a   Lohmann, Christine ^a   Akhmedov, Alexander ^a   Spescha, Remo ^a   Elliott, Peter J ^c   Westphal, Christoph H ^c   Matter, Christian M ^a,b   Lscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GLAXOSMITHKLINE   (United States)

Author keywords

NF B; Sirt1; Thrombosis; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; COMPLEMENTARY DNA; ENZYME INHIBITOR; FIREFLY LUCIFERASE; HISTAMINE; HISTONE DEACETYLASE; I KAPPA B ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RESVERATROL; ROSE BENGAL; SIRTINOL; SIRTUIN 1; SMALL INTERFERING RNA; SPLITOMICIN; STRESS ACTIVATED PROTEIN KINASE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; C57BL 6 MOUSE; CAROTID ARTERY THROMBOSIS; CELL CULTURE; CELL STIMULATION; COLORIMETRY; CONTROLLED STUDY; DNA BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

ANIMALS; BENZAMIDES; BINDING SITES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATORS; GENES, REPORTER; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHALENES; NAPHTHOLS; PROMOTER REGIONS, GENETIC; PYRONES; RNA INTERFERENCE; RNA, MESSENGER; SIRTUIN 1; STILBENES; THROMBOPLASTIN; THROMBOSIS; TRANSCRIPTION FACTOR RELA; TRANSFECTION;

EID: 78751516833     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq339     Document Type: Article

References (47)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
2. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-731.
3. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006;32:5-10.
4. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-599.
5. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
6. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissuefactor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-771.
7. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 2006;114:1512-1521.
8. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 2005;112: 341-349.
9. Steffel J, Arnet C, Akhmedov A, Iseli SM, Luscher TF, Tanner FC. Histamine differentially interacts with tumor necrosis factor-alpha and thrombin in endothelial tissue factor induction: the role of c-Jun NH2-terminal kinase. J Thromb Haemost 2006;4: 2452-2460.
10. Gasser SM, Cockell MM. The molecular biology of the SIR proteins. Gene 2001;279: 1-16.
11. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008;7:841-853.
12. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403: 795-800.
13. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu Wet al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004;116:551-563.
14. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-148.
15. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-776.
16. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007;104:14855-14860.
17. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-2380.
18. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521.
19. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007;43: 571-579.
20. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-1122.
21. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008;80:191-199.
22. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450:712-716.
23. Breitenstein A, Stampfli SF, Camici GG, Akhmedov A, Ha HR, Follath F et al. Amiodarone inhibits arterial thrombus formation and tissue factor translation. Arterioscler Thromb Vasc Biol 2008;28:2231-2238.
24. Buerki C, Rothgiesser KM, Valovka T, Owen HR, Rehrauer H, Fey M et al. Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res 2008;36:1665-1680.
25. Stein S, Schafer N, Breitenstein A, Besler C, Winnik S, Lohmann C et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany NY) 2010;2:353-360.
26. Holy EW, Akhmedov A, Luscher TF, Tanner FC. Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. J Mol Cell Cardiol 2009;46: 234-240.
27. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O et al. CellPro- filer: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006;7:R100.
28. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-1013.
29. Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, Kashiwaya Y et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 2003;12: 51-62.
30. Grubisha O, Smith BC, Denu JM. Small molecule regulation of Sir2 protein deacetylases. FEBS J 2005;272:4607-4616.
31. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392-401.
32. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005;280:40364-40374.
33. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000;101:2144-2148.
34. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S,Weitz JI et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-1741.
35. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
36. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005;105:192-198.
37. Pedersen B, Holscher T, Sato Y, Pawlinski R, Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 2005;105:2777-2782.
38. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105: 1135-1143.
39. Reilly MP, Rohatgi A, McMahon K, Wolfe ML, Pinto SC, Rhodes T et al. Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. J Investig Med 2007;55: 26-35.
40. Annex BH, Denning SM, Channon KM, Sketch MH Jr., Stack RS, Morrissey JH et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91: 619-622.
41. Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, Rossetti L et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008;8:333-341.
42. Lee JH, Song MY, Song EK, Kim EK, Sung Moon W, Han MK et al. Overexpression of SIRT1 protects pancreatic {beta}-cells against cytokine toxicity through suppressing NF-{kappa}B signaling pathway. Diabetes 2009;58:344-351.
43. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005;120: 473-482.
44. Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA 2007; 297: 986-994.
45. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002;106:2442-2447.
46. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004;109:2524-2528.
47. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003;92:400-405.